{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.69","upperLimit":"40.25","value":"34.40"},{"groupId":"OG001","lowerLimit":"19.61","upperLimit":"29.37","value":"23.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"Overall survival is defined as the time, in months, from randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Daratumumab subcutaneously (fixed dose of 1800 mg) or intravenously (16 mg/kg) weekly for cycles 1-2, every 2 weeks for cycles 3-6, and every 4 weeks thereafter. Pomalidomide was administered at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone at 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles..\n\nPomalidomide: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.\n\nDexamethasone: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Daratumumab+Pomalidomide+Dexamethasone"},{"description":"Patients received Pomalidomide at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles","id":"OG001","title":"Pomalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Final OS analysis with the CCO of 31 May 2022 and a median (range) follow-up of 39.6 (0.1-56.9) months","reportingStatus":"POSTED","timeFrame":"From randomization until death from any cause (up to 5 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}